Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia.

DeAngelo DJ, Walker AR, Schlenk RF, Sierra J, Medeiros BC, Ocio EM, Röllig C, Strickland SA, Thol F, Valera SZ, Dasgupta K, Berkowitz N, Stuart RK.

Leuk Res. 2019 Aug 1;85:106197. doi: 10.1016/j.leukres.2019.106197. [Epub ahead of print]

PMID:
31541945
2.

Genomic landscape of neutrophilic leukemias of ambiguous diagnosis.

Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister Schultz A, Long N, White L, Carlos A, Henson R, Lin C, Searles R, Collins RH, DeAngelo DJ, Deininger MW, Dunn T, Hein T, Luskin MR, Medeiros BC, Oh ST, Pollyea DA, Steensma DP, Stone RM, Druker BJ, McWeeney SK, Maxson JE, Gotlib JR, Tyner JW.

Blood. 2019 Sep 12;134(11):867-879. doi: 10.1182/blood.2019000611. Epub 2019 Jul 31.

PMID:
31366621
3.

Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin.

Narayan R, Olsson N, Wagar LE, Medeiros BC, Meyer E, Czerwinski D, Khodadoust MS, Zhang L, Schultz L, Davis MM, Elias JE, Levy R.

PLoS One. 2019 Jul 10;14(7):e0219547. doi: 10.1371/journal.pone.0219547. eCollection 2019.

4.

Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database.

Pandya BJ, Chen CC, Medeiros BC, McGuiness CB, Wilson S, Horvath Walsh LE, Wade RL.

Adv Ther. 2019 Aug;36(8):1922-1935. doi: 10.1007/s12325-019-01003-7. Epub 2019 Jun 20.

PMID:
31222713
5.

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia.

Medeiros BC, Chan SM, Daver NG, Jonas BA, Pollyea DA.

Am J Hematol. 2019 Jul;94(7):803-811. doi: 10.1002/ajh.25484. Epub 2019 May 1. Review.

6.

Addressing the room for improvement in management of acute promyelocytic leukemia.

Nørgaard JM, Friis LS, Kristensen JS, Severinsen MT, Mølle I, Marcher CW, Møller P, Schoellkopf C, Nielsen OJ, Preiss BS, Andersen MK, Kjeldsen E, Medeiros BC, Østgård LSG; Danish Acute Leukemia Group.

Eur J Haematol. 2019 Jun;102(6):479-485. doi: 10.1111/ejh.13229. Epub 2019 Apr 7.

PMID:
30887583
7.

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study.

Garcia-Manero G, Abaza Y, Takahashi K, Medeiros BC, Arellano M, Khaled SK, Patnaik M, Odenike O, Sayar H, Tummala M, Patel P, Maness-Harris L, Stuart R, Traer E, Karamlou K, Yacoub A, Ghalie R, Giorgino R, Atallah E.

Blood Adv. 2019 Feb 26;3(4):508-518. doi: 10.1182/bloodadvances.2018027409.

8.

Treatment patterns in patients with acute myeloid leukemia in the United States: a cross-sectional, real-world survey.

Medeiros BC, Pandya BJ, Hadfield A, Pike J, Wilson S, Mueller C, Bui CN, Flanders SC, Rider A, Horvath Walsh LE.

Curr Med Res Opin. 2019 May;35(5):927-935. doi: 10.1080/03007995.2019.1578152. Epub 2019 Mar 19.

PMID:
30712406
9.

The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900).

Medeiros BC, Othus M, Tallman MS, Sun Z, Fernandez HF, Rowe JM, Lazarus HM, Appelbaum FR, Luger SM, Litzow MR, Erba HP.

Leuk Res. 2019 Mar;78:29-33. doi: 10.1016/j.leukres.2019.01.007. Epub 2019 Jan 17.

10.

Is there a standard of care for relapsed AML?

Medeiros BC.

Best Pract Res Clin Haematol. 2018 Dec;31(4):384-386. doi: 10.1016/j.beha.2018.09.006. Epub 2018 Sep 20. Review.

PMID:
30466752
11.

NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study.

Østgård LSG, Nørgaard M, Pedersen L, Østgård R, Friis LS, Schöllkopf C, Severinsen MT, Marcher CW, Medeiros BC, Jensen MK.

Cancer Manag Res. 2018 Oct 29;10:5043-5051. doi: 10.2147/CMAR.S165498. eCollection 2018.

12.

Functional genomic landscape of acute myeloid leukaemia.

Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK 5th, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ.

Nature. 2018 Oct;562(7728):526-531. doi: 10.1038/s41586-018-0623-z. Epub 2018 Oct 17.

13.

Chemotherapy based combinations in AML: Time to take a step back?

Medeiros BC.

Leuk Res. 2018 Oct;73:39-40. doi: 10.1016/j.leukres.2018.08.018. Epub 2018 Aug 31. No abstract available.

PMID:
30212655
14.

Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial.

Bixby D, Noppeney R, Lin TL, Cortes J, Krauter J, Yee K, Medeiros BC, Krämer A, Assouline S, Fiedler W, Dimier N, Simmons BP, Riehl T, Colburn D.

Br J Haematol. 2019 May;185(3):595-598. doi: 10.1111/bjh.15571. Epub 2018 Sep 11. No abstract available.

PMID:
30203489
15.

Non-zero-sum game of transfusions: EOL in leukemia.

Medeiros BC.

Blood. 2018 Aug 16;132(7):676-678. doi: 10.1182/blood-2018-06-856336. No abstract available.

PMID:
30115633
16.

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.

Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, Medeiros BC.

J Clin Oncol. 2018 Sep 10;36(26):2684-2692. doi: 10.1200/JCO.2017.77.6112. Epub 2018 Jul 19.

17.

A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.

Dinner S, Dunn TJ, Price E, Coutré SE, Gotlib J, Berube C, Kaufman GP, Medeiros BC, Liedtke M.

Int J Hematol. 2018 Sep;108(3):267-273. doi: 10.1007/s12185-018-2468-5. Epub 2018 May 25.

PMID:
29802551
18.

Associations between cohabitation status, treatment, and outcome in AML patients: a national population-based study.

Østgård LSG, Nørgaard M, Medeiros BC, Severinsen MT, Friis LS, Marcher CW, Schoellkopf C, Nørgaard JM.

Blood. 2018 Jun 14;131(24):2730-2733. doi: 10.1182/blood-2017-11-814327. Epub 2018 Apr 25. No abstract available.

PMID:
29695517
19.

A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia.

Medeiros BC, Tanaka TN, Balaian L, Bashey A, Guzdar A, Li H, Messer K, Ball ED.

Clin Lymphoma Myeloma Leuk. 2018 May;18(5):346-352.e5. doi: 10.1016/j.clml.2018.02.017. Epub 2018 Mar 2.

PMID:
29572158
20.

Interpretation of clinical endpoints in trials of acute myeloid leukemia.

Medeiros BC.

Leuk Res. 2018 May;68:32-39. doi: 10.1016/j.leukres.2018.02.002. Epub 2018 Feb 7. Review.

21.

Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national population-based case-control study.

Østgård LSG, Nørgaard M, Pedersen L, Østgård RD, Medeiros BC, Overgaard UM, Schöllkopf C, Severinsen M, Marcher CW, Jensen MK.

Br J Haematol. 2018 Apr;181(2):205-214. doi: 10.1111/bjh.15163. Epub 2018 Mar 5.

PMID:
29504124
22.

Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing.

Medeiros BC, Possick J, Fradley M.

Blood Rev. 2018 Jul;32(4):289-299. doi: 10.1016/j.blre.2018.01.004. Epub 2018 Feb 3. Review.

23.

Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).

Advani AS, Li H, Michaelis LC, Medeiros BC, Liedtke M, List AF, O'Dwyer K, Othus M, Erba HP, Appelbaum FR.

Leuk Res. 2018 Apr;67:17-20. doi: 10.1016/j.leukres.2018.01.021. Epub 2018 Jan 31.

24.

Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm.

Walter RB, Othus M, Orlowski KF, McDaniel EN, Scott BL, Becker PS, Percival MM, Hendrie PC, Medeiros BC, Chiarella MT, Louie AC, Estey EH.

Haematologica. 2018 Mar;103(3):e106-e109. doi: 10.3324/haematol.2017.182642. Epub 2017 Dec 14. No abstract available.

25.

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia.

Medeiros BC, McCaul K, Kambhampati S, Pollyea DA, Kumar R, Silverman LR, Kew A, Saini L, Beach CL, Vij R, Wang X, Zhong J, Gale RP.

Haematologica. 2018 Jan;103(1):101-106. doi: 10.3324/haematol.2017.172353. Epub 2017 Nov 2.

26.

Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: A National Population-Based Cohort Study.

Østgård LSG, Lund JL, Nørgaard JM, Nørgaard M, Medeiros BC, Nielsen B, Nielsen OJ, Overgaard UM, Kallenbach M, Marcher CW, Riis AH, Sengeløv H.

Biol Blood Marrow Transplant. 2018 Feb;24(2):314-323. doi: 10.1016/j.bbmt.2017.10.019. Epub 2017 Oct 16.

27.

Effects of Education and Income on Treatment and Outcome in Patients With Acute Myeloid Leukemia in a Tax-Supported Health Care System: A National Population-Based Cohort Study.

Østgård LSG, Nørgaard M, Medeiros BC, Friis LS, Schoellkopf C, Severinsen MT, Marcher CW, Nørgaard JM.

J Clin Oncol. 2017 Nov 10;35(32):3678-3687. doi: 10.1200/JCO.2017.73.6728. Epub 2017 Sep 11.

PMID:
28892433
28.

Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality.

Sorror ML, Storer BE, Fathi AT, Gerds AT, Medeiros BC, Shami P, Brunner AM, Sekeres MA, Mukherjee S, Peña E, Elsawy M, Wardyn S, Whitten J, Moore R, Becker PS, McCune JS, Appelbaum FR, Estey EH.

JAMA Oncol. 2017 Dec 1;3(12):1675-1682. doi: 10.1001/jamaoncol.2017.2714.

29.

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.

Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, English I, Ho H, Pandya R, Bolosky WJ, Poon H, Deininger MW, Collins R, Swords RT, Watts J, Pollyea DA, Medeiros BC, Traer E, Tognon CE, Mori M, Druker BJ, Tyner JW.

Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):E7554-E7563. doi: 10.1073/pnas.1703094114. Epub 2017 Aug 7.

30.

Long non-coding RNAs: another brick in the wall of normal karyotype acute myeloid leukemia?

Medeiros BC.

Haematologica. 2017 Aug;102(8):1301-1303. doi: 10.3324/haematol.2017.171744. No abstract available.

31.

Localized skin-limited blastic plasmacytoid dendritic cell neoplasm: A subset with possible durable remission without transplantation.

Amitay-Laish I, Sundram U, Hoppe RT, Hodak E, Medeiros BC, Kim YH.

JAAD Case Rep. 2017 Jul 19;3(4):310-315. doi: 10.1016/j.jdcr.2017.03.015. eCollection 2017 Jul. No abstract available.

32.

Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function.

Zhang H, Means S, Schultz AR, Watanabe-Smith K, Medeiros BC, Bottomly D, Wilmot B, McWeeney SK, Kükenshöner T, Hantschel O, Tyner JW.

Cancer Res. 2017 Aug 15;77(16):4258-4267. doi: 10.1158/0008-5472.CAN-17-1052. Epub 2017 Jun 26.

33.

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.

Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H.

N Engl J Med. 2017 Aug 3;377(5):454-464. doi: 10.1056/NEJMoa1614359. Epub 2017 Jun 23.

34.

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK, Stone RM, DeAngelo DJ, Levine RL, Flinn IW, Kantarjian HM, Collins R, Patel MR, Frankel AE, Stein A, Sekeres MA, Swords RT, Medeiros BC, Willekens C, Vyas P, Tosolini A, Xu Q, Knight RD, Yen KE, Agresta S, de Botton S, Tallman MS.

Blood. 2017 Aug 10;130(6):722-731. doi: 10.1182/blood-2017-04-779405. Epub 2017 Jun 6.

35.

Novel Therapeutics in Acute Myeloid Leukemia.

DiNardo CD, Stone RM, Medeiros BC.

Am Soc Clin Oncol Educ Book. 2017;37:495-503. doi: 10.14694/EDBK_175401. Review.

PMID:
28561688
36.

A study of disseminated intravascular coagulation in acute leukemia reveals markedly elevated D-dimer levels are a sensitive indicator of acute promyelocytic leukemia.

Shahmarvand N, Oak JS, Cascio MJ, Alcasid M, Goodman E, Medeiros BC, Arber DA, Zehnder JL, Ohgami RS.

Int J Lab Hematol. 2017 Aug;39(4):375-383. doi: 10.1111/ijlh.12636. Epub 2017 Apr 19.

PMID:
28422420
37.

Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia.

Carey A, Edwards DK 5th, Eide CA, Newell L, Traer E, Medeiros BC, Pollyea DA, Deininger MW, Collins RH, Tyner JW, Druker BJ, Bagby GC, McWeeney SK, Agarwal A.

Cell Rep. 2017 Mar 28;18(13):3204-3218. doi: 10.1016/j.celrep.2017.03.018.

38.

Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.

Swords RT, Watts J, Erba HP, Altman JK, Maris M, Anwer F, Hua Z, Stein H, Faessel H, Sedarati F, Dezube BJ, Giles FJ, Medeiros BC, DeAngelo DJ.

Blood Cancer J. 2017 Feb 3;7(2):e520. doi: 10.1038/bcj.2017.1. No abstract available.

39.

NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016.

VanderWalde N, Jagsi R, Dotan E, Baumgartner J, Browner IS, Burhenn P, Cohen HJ, Edil BH, Edwards B, Extermann M, Ganti AK, Gross C, Hubbard J, Keating NL, Korc-Grodzicki B, McKoy JM, Medeiros BC, Mrozek E, O'Connor T, Rugo HS, Rupper RW, Shepard D, Silliman RA, Stirewalt DL, Tew WP, Walter LC, Wildes T, Bergman MA, Sundar H, Hurria A.

J Natl Compr Canc Netw. 2016 Nov;14(11):1357-1370.

PMID:
27799507
40.

Why do subjects on clinical trials discontinue therapy? Do we really know?

Medeiros BC, Gale RP.

Leuk Res. 2016 Dec;51:19-21. doi: 10.1016/j.leukres.2016.10.006. Epub 2016 Oct 17. No abstract available.

PMID:
27776289
41.

Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients.

Østgård LS, Nørgaard M, Sengeløv H, Medeiros BC, Kjeldsen L, Overgaard UM, Severinsen MT, Marcher CW, Jensen MK, Nørgaard JM.

Oncotarget. 2016 Nov 1;7(44):72044-72056. doi: 10.18632/oncotarget.12495.

42.

Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells.

Huang M, Garcia JS, Thomas D, Zhu L, Nguyen LX, Chan SM, Majeti R, Medeiros BC, Mitchell BS.

Oncotarget. 2016 Nov 15;7(46):74917-74930. doi: 10.18632/oncotarget.12493.

43.

Isocitrate dehydrogenase mutations in myeloid malignancies.

Medeiros BC, Fathi AT, DiNardo CD, Pollyea DA, Chan SM, Swords R.

Leukemia. 2017 Feb;31(2):272-281. doi: 10.1038/leu.2016.275. Epub 2016 Oct 10. Review.

44.

Identification of Doxorubicin as an Inhibitor of the IRE1α-XBP1 Axis of the Unfolded Protein Response.

Jiang D, Lynch C, Medeiros BC, Liedtke M, Bam R, Tam AB, Yang Z, Alagappan M, Abidi P, Le QT, Giaccia AJ, Denko NC, Niwa M, Koong AC.

Sci Rep. 2016 Sep 16;6:33353. doi: 10.1038/srep33353.

45.

Management of invasive Aspergillosis in acute myelogenous leukemia.

Medeiros BC.

Clin Adv Hematol Oncol. 2016 Jul;14(7):502-4. No abstract available.

PMID:
27379944
46.

Individualizing Therapeutic Strategies in Acute Myeloid Leukemia: Moving Beyond the 'One-Size-Fits-All' Approach.

Jonas BA, Medeiros BC.

Oncology (Williston Park). 2016 Apr;30(4):330, 333. No abstract available.

47.

A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.

Dunn TJ, Dinner S, Price E, Coutré SE, Gotlib J, Hao Y, Berube C, Medeiros BC, Liedtke M.

Br J Haematol. 2016 Apr;173(2):253-9. doi: 10.1111/bjh.13946. Epub 2016 Apr 4.

PMID:
27040320
48.

Predictors of early death and survival among children, adolescents and young adults with acute myeloid leukaemia in California, 1988-2011: a population-based study.

Abrahão R, Keogh RH, Lichtensztajn DY, Marcos-Gragera R, Medeiros BC, Coleman MP, Ribeiro RC, Keegan TH.

Br J Haematol. 2016 Apr;173(2):292-302. doi: 10.1111/bjh.13944. Epub 2016 Feb 5.

49.

Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies.

Lewinsohn M, Brown AL, Weinel LM, Phung C, Rafidi G, Lee MK, Schreiber AW, Feng J, Babic M, Chong CE, Lee Y, Yong A, Suthers GK, Poplawski N, Altree M, Phillips K, Jaensch L, Fine M, D'Andrea RJ, Lewis ID, Medeiros BC, Pollyea DA, King MC, Walsh T, Keel S, Shimamura A, Godley LA, Hahn CN, Churpek JE, Scott HS.

Blood. 2016 Feb 25;127(8):1017-23. doi: 10.1182/blood-2015-10-676098. Epub 2015 Dec 28.

50.

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Myeloproliferative Neoplasms.

Kelley TW, Arber DA, Gibson C, Jones D, Khoury JD, Medeiros BC, O'Malley DP, Patel KP, Pilichowska M, Vasef MA, Wallentine J, Zehnder JL.

Arch Pathol Lab Med. 2016 Jul;140(7):675-7. doi: 10.5858/arpa.2015-0400-CP. Epub 2015 Dec 11. No abstract available.

Supplemental Content

Loading ...
Support Center